Fennec Pharmaceuticals (FENC) Short term Debt (2021 - 2022)
Fennec Pharmaceuticals (FENC) posted Short term Debt of $25.0 million for Q4 2022, up 2400.0% on a QoQ basis from $1.0 million in Q2 2022, and up 1263.88% year-over-year from $1.8 million in Q4 2021.
Fennec Pharmaceuticals (FENC) Short term Debt (2021 - 2022) Analysis & Trends
Fennec Pharmaceuticals' Short term Debt history runs 2 years deep, the most recent figure standing at $25.0 million for Q4 2022.
- Quarterly Short term Debt rose 1263.88% year-over-year to $25.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $25.0 million (up 1263.88% YoY) and the FY2022 annual result came in at $25.0 million, up 1263.88% from the prior year.
- Short term Debt was $25.0 million for Q4 2022 at Fennec Pharmaceuticals, up from $1.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $25.0 million in Q4 2022 and bottomed at $500000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fennec Pharmaceuticals | 346.75 Mn | 309.97 Mn | 12.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 25.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 2.00 Mn |